Found: 7
Select item for more details and to access through your institution.
Pediatric Vaccines and Cost-Effectiveness Thresholds: How Much is Too Much to Pay for Prevention?
- Published in:
- Infectious Diseases & Therapy, 2021, v. 10, n. 1, p. 1, doi. 10.1007/s40121-020-00367-6
- By:
- Publication type:
- Article
Cost-Effectiveness of Pazopanib in Advanced Soft Tissue Sarcoma in the United Kingdom.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Cost-Effectiveness of Pazopanib in Advanced Soft Tissue Sarcoma in the United Kingdom.
- Published in:
- Sarcoma, 2014, p. 1, doi. 10.1155/2014/481071
- By:
- Publication type:
- Article
Cost Effectiveness of Dabrafenib as a First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in Canada.
- Published in:
- PharmacoEconomics, 2015, v. 33, n. 4, p. 367, doi. 10.1007/s40273-014-0241-z
- By:
- Publication type:
- Article
Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma.
- Published in:
- Oncology & Therapy, 2016, v. 4, n. 2, p. 239, doi. 10.1007/s40487-016-0030-2
- By:
- Publication type:
- Article
Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom.
- Published in:
- PLoS ONE, 2017, v. 12, n. 6, p. 1, doi. 10.1371/journal.pone.0175920
- By:
- Publication type:
- Article